

# GHWP

## 26th Annual Meeting



**Working Group1 Updates**

Feb. 15<sup>th</sup>, 2023

# Membership Update

## Working Group 1

### Chair

**Dr. Seil Park**

Ministry of Food and Drug Safety, Korea

### Co-Chair

**Ms. Mandy MyoungShim Kim**

Johnson & Johnson MedTech


### Secretary

**Ms. Anna Yesong Park**

Johnson & Johnson MedTech

### WG1 Members (Total: 40)

Abbott,  
BD,  
Brandwood Biomedical,  
Cook,  
Cordis,  
Elekta,  
FUJIFILM,  
Grifols,  
ILOODA,  
J&J,  
Philips,  
Qserve,  
Regulatory Associates LLP,  
Seqpro,  
Siemens,  
Smith & Nephew,  
Teleflex,  
3M,  
Varian,






Indonesia,  
Kazakhstan,  
Kenya,  
Oman,  
Saudi Arabia,  
South Korea,  
Tanzania,  
US

# Proposed Work Items

**WG1, 2020-2022**



# Proposed Work Plan

(WG1, 2020-2022)

Work Item	Deliverables	Key Milestones & Progress
<b>Revisit WG1 documents</b>	Revise 'Handbook for Approval of Patient-matched Medical Devices Using 3D Printers'	<ul style="list-style-type: none"> <li>• Revision completion (2020)               <ul style="list-style-type: none"> <li>✓ Referred IMDRF guidance document to harmonize terms and definitions</li> <li>✓ Added section of reference</li> <li>✓ Added additional points of consideration and standardized terminology</li> </ul> </li> </ul> 
	Revise 'Guidance for Minor Change Reporting' ; comparing to AHWP/WG2-WG1-WG3/F001:2019 ( <a href="#">Categorisation of Changes to a Registered Medical Device</a> )	<ul style="list-style-type: none"> <li>• Revision completion (2020)               <ul style="list-style-type: none"> <li>✓ Added section of scope based on AHWP/WG2-WG1-WG3/F001:2019</li> <li>✓ Revised ambiguous terminology and added additional explanation</li> </ul> </li> </ul> 
<b>Document Development of EUA</b>	Support document development driven by the joint WG1-3 for EUA(Emergency Use of Authorization)	<ul style="list-style-type: none"> <li>• Document development completion (2021)               <ul style="list-style-type: none"> <li>✓ Investigated and shared the status of EUA in AP economies</li> <li>✓ Developed 'Regulatory mechanism for Medical Devices including In Vitro Diagnostic Medical Devices and Software as Medical Devices during a public health emergency'</li> </ul> </li> </ul> 

# Proposed Work Plan

(WG1, 2020-2022)

Work Item	Deliverables	Key Milestones & Progress
<p>Revisit documents co-worked by WG1,2, and 3</p>	<p>Revise 'Categorisation of Changed to a Registered Medical Device'</p>	<ul style="list-style-type: none"> <li>• Revision completion (2022), <b>expected to be endorsed</b> <ul style="list-style-type: none"> <li>✓ Added examples, especially in AI, Software, and Cybersecurity</li> <li>✓ Added references</li> <li>✓ Corrected flow charts of changes</li> </ul> </li> </ul> 
	<p>Revise 'Principles of Regulatory Requirements for Electronic Instructions for Use (eIFU) (AHWP/WG1-WG2-WG3/F002: 2019)</p> <p>Review the opportunity to modify or obsolete on 'Regulatory and treatment of e-IFU and e-Label of Medical Devices – Review of International Practice' (AHWP/WG1-WG2/F001:2017)</p>	<ul style="list-style-type: none"> <li>• Discussed to find out how the current regulations/guidelines are described in regards to user limitation, scope, benefit, and implementation of eIFU</li> <li>• Developed the survey questions for current approaches</li> <li>• Circulated survey and collected feedback from WG1,2, and 3 jurisdictions</li> <li>• Composed drafting committee</li> <li>• Plan to revise the document by 2023</li> </ul> 

# Activities

WG1, 2022

# 2022 Activities

## Working Group 1



# 2022 Activities

## Working Group 1

- ✓ **WG1 regular meeting (bi-monthly)**
- ✓ **Joint meeting with WG2/3**
- ✓ **Sub-work item meeting (monthly)**
- ✓ **WG TC call**





# Work Items Update

WG1, 2022

# Proposed Work Item for Endorsement

Working Group 1

## WG1-2-3 Joint Work Item



**Revisit a GHWP Document  
"Categorisation of Changes to  
a Registered Medical Device,  
AHWP/WG2-WG1-  
WG3/F001:2019"**

### < Deliverables >

Update examples, especially in AI, Software, and Cybersecurity from WG1, 2, and 3 referring to various jurisdictions, including non-member economies across the globe

### < Key Milestone >

- Submitted NWIP form
- Collect examples from WG1,2, and 3
- Aligned the scope, Shared action items/plan and interim output with WGs in regular meetings
- Revised GHWP Guidance, Submitted the proposed doc. for endorsement

# Proposed Work Item for Endorsement

## Revisit a GHWP Document "Categorisation of Changes to a Registered Medical Device"

### Examples Added to 5.4.4 Changes to Software


#### Non-significant

- Changes in operating environment, graphic interface, languages & translation, or storage methods w/o its safety and performance
- Changes in software to strengthen the cybersecurity such as adding encryption, passcode requirements, adding timeout, or changing the access of restricted user
- Changes in software to disallow use of specific characters to prevent ID barcode info truncation
- Changes in software to correct fluid bottle size parameter
- Changes in IVD analyzer software to prevent data merging or correct requirements to modify code in the control unit w/o modifying the core algorithm
- Changes in training dataset of a Machine Learning MD Software w/o any changes to labeled product design specification

#### Significant

- Changes in software to add product indication for use or its operating principles including diagnostic algorithm

GHWP/WG2-WG1-WG3/P001:2023

  
**GHWP**  
**Global Harmonization Working Party**  
Towards Medical Device Harmonization

**PROPOSED DOCUMENT**

**Title:** Categorisation of Changes to a Registered Medical Device

**Authoring Group:** Work Group 1, Pre-market: General MD  
Work Group 2, Pre-market: IVD  
Work Group 3, Pre-market: Software as a MD

**Date:** 7 Feb 2023

Dr. Wen-Wei Tsai  
*Chair, Work Group 2*  
Dr. Se-Il Park  
*Chair, Work Group 1*  
Dr. Abdullatif S. AlWatban  
*Chair, Work Group 3*

Copyright © 2023 by the Global Harmonization Working Party  
All Rights Reserved

# Proposed Work Item for Endorsement

## Revisit a GHWP Document "Categorisation of Changes to a Registered Medical Device"

Categorisation of Changes to a Registered Medical Device GHWP/WG2-WG1-WG3/P001-2023		Categorisation of Changes to a Registered Medical Device GHWP/WG2-WG1-WG3/P001-2023		Categorisation of Changes to a Registered Medical Device GHWP/WG2-WG1-WG3/P001-2023	
<b>5.4.4 Changes to Software</b>					
<b>Example</b>	<b>Category (Significant / Non-Significant)</b>	<b>Example</b>	<b>Category</b>	<b>Example</b>	<b>Category</b>
Change to software which impacts the control of the device that may alter diagnostic or therapeutic function, such as: <i>Software change canceling the change of critical steps for laser delivery on eye treatment</i>	Significant	Change to software incorporating a change to the operation system platform, such as: <i>A change in the software together with operating system change from Linux to another operating system platform.</i>	Significant	Change in IVD analyzer software to rewrite an incorrectly worded software requirement and to modify code in the control unit of the analyzer without modifying the core algorithm (such as detection or measurement module algorithm).	Non-significant
Change to software initiated by manufacturer that modifies the algorithm that affects the diagnostic or therapeutic function, such as: <i>An X-ray Lung Nodule Assessment Software is used along with a Digital Radiography System to support physicians in the visualization, identification, evaluation and reporting of pulmonary lesions modules in chest images. An algorithm change improves the detection rate for small nodules.</i>	Significant	Addition, change, and deletion of OS version(s) (operating environment) within the same platform such as: <i>When Windows X is added for a product for which Windows 7 is specified as an OS</i>	Non-significant	Changes in software including the addition of product indication for use or its operating principles including diagnostic algorithm such as machine learning that may alter diagnostic or therapeutic function.	Significant
Change to software with addition of new features or software applications that affect any diagnostic or therapeutic functions of a medical device, such as: <i>Insulin Pump - Software changes that allow for wireless communication with compatible (continuous) blood glucose monitors.</i>	Significant	Change in software to alter colors and location of menu on graphic user interface of medical devices that does not affect safety and performance of the device but results in version change	Non-significant	Change in accuracy of Machine Learning Medical Device software via modification and expansion of the training dataset without any changes to labeled product design specification.	Non-Significant
Change to software that includes addition or removal of alarm function, such that a response to this change affect the treatment of patient, such as: <i>Electrocardiogram Addition to software of an early warning alarm to signal a potential cardiac event such as atrial fibrillation.</i>	Significant	Change in software to add languages for users that does not accompany changes in the main features and misunderstanding in translation for intended use, principle of operation, and performance	Non-significant		
Change to software that affect the safety and performance of the registered medical device such that treatment or diagnosis of the patient is altered, such as:  1. <i>Blood Oxygen Monitor - A software change that allows the monitor to report blood CO2 concentrations with higher accuracy up to 0.5% deviation.</i>  2. <i>Upgrade of software version changes the performance characteristics like specificity or sensitivity of the In-vitro diagnostic medical device.</i>	Significant	Change in the distribution/storage method of software among physical media (USB, CD, DVD), digital means (download), etc.	Non-significant		
<i>A single bug fix to correct the display error on the data table from the software analysis result.</i>	Non-significant	Change in software to strengthen the cybersecurity such as: 1. <i>Adding encryption to the configuration file of the device.</i> 2. <i>Adding password requirements for remote users, in addition to the password needed to access the device, and</i> 3. <i>Adding a timeout for remote user or changing the access of the restricted user/customer to appropriate levels.</i>	Non-significant		
<i>Change in software which only introduces non-therapeutic and non-diagnostic features such as printing, faxing, improved image clarity or reporting format</i>	Non-significant	Change in software to disable use of the specific characters that are invalid as defined in the instrument host interface specification for the prevention of Specimen Identification (ID) barcode information truncation	Non-significant		
<i>Change in software to disable certain functions that does not interact with other functions</i>	Non-significant	Change in software to return the system into specification of the most recently cleared device regarding DICOM(Digital Imaging and Communications in Medicine standard: <a href="http://dicom.nema.org/">http://dicom.nema.org/</a> ) conformance allowing the automatic fetching of prior studies from radiology information system using PACS (Picture Archiving and Communication System).	Non-significant		
		Change in software to correct the bottle size parameter of the cleaning solution to prevent the fluid detection errors.	Non-significant		
		Change in IVD analyzer software to ensure new data of the administrative records for reagents is not merged with the existing data in the table within the software by correcting software code in the control unit of the analyzer to modify the table to add new columns.	Non-significant		

### References

- Japan: PMDA document (PSEHB/MDED Notification No. 1020-1) - Handling of procedures for minor changes made in association with partial changes of medical device programs – October 20, 2017
- US: Guidance for Industry and FDA Staff – Deciding When to Submit a 510(k) for a Software Change to an Existing Device – October 25, 2017
- Korea: Guidance for Review and Approval of Artificial Intelligence-Enabled Medical Devices, May-2022

### WG1-2-3 Joint Work Item



#### Revisit a GHWP Document 'Principles of Regulatory Requirements for Electronic Instructions for Use (eIFU):2019'

#### < Deliverables >

Revisit WG1 Document to see the opportunity to modify or obsolete, reviewing consideration on risk factors and current approaches in established jurisdictions

#### < Key Milestone >

- Submitted NWIP form
- Developed the survey questions for current approaches
- Circulated survey and collected the feedback of WG1,2, and 3 jurisdictions
- Composed drafting committee

# Proposed Work Item (ongoing)


## Revisit “Principles of Regulatory Requirements for Electronic Instructions for Use (eIFU)”

### e-IFU may be permitted:

- To all users, or none
- for Professional Users only

### e-IFU may be permitted:

- For all devices, or not at all
- Only for professional use devices
- Only for specific device types e.g.:
  - implants
- For software devices
- For devices with a screen
- Fixed installed devices



- On hard media such as DVDs, USB
- As downloadable document (e.g. PDF)
- As web page
- Embedded in a device and displayed through user interface

- Availability of paper copy on request

# Proposed Work Item (ongoing)

Revisit “Principles of Regulatory Requirements for Electronic Instructions for Use (eIFU)”

## Risk Factors of e-IFU Implementation

Quality Systems	Physical Impact	Cyber Risks	Paper Copies	Online Supply	Content
<ul style="list-style-type: none"> <li>• Validation of e-IFU</li> <li>• Accuracy</li> <li>• Languages and translations</li> <li>• Method of delivery and user instructions on how</li> <li>• Change management</li> <li>• Identification of versions and...</li> <li>• avoiding mix ups</li> </ul>	<ul style="list-style-type: none"> <li>• Sterility revalidation if paper copy is removed</li> <li>• Advice on location of e-IFU on physical packaging</li> </ul>	<ul style="list-style-type: none"> <li>• Online security – cannot be removed or replaced.</li> <li>• Archival procedures</li> <li>• Privacy – e.g. impact of cookies placed on visit to e-IFU website</li> </ul>	<ul style="list-style-type: none"> <li>• Timeline for provision on request</li> <li>• Ensuring equivalence of paper and e-IFU</li> </ul>	<ul style="list-style-type: none"> <li>• Need to be easy to find by simple web search, e.g. &lt;manufacturer name&gt; + &lt;device name&gt; + “IFU”</li> </ul>	<ul style="list-style-type: none"> <li>• Same content requirements and use standard symbols as for paper labelling</li> </ul>

# Proposed Work Item (ongoing)

## Revisit “Principles of Regulatory Requirements for Electronic Instructions for Use (eIFU)”





## Revisit “Principles of Regulatory Requirements for Electronic Instructions for Use (eIFU)”

### Survey Circulation

User scope of eIFU, Device Scope of e-IFU, e-IFU formats, Risk mitigation, QMS requirements, Hard copy supply and equivalence, and Contents of e-IFU

Survey Template - eIFU <sup>1,2</sup>				
Item <sup>1,2</sup>	Question <sup>1,2</sup>	Name and Regulation deployment in your jurisdiction. (Country, Y/N) <sup>1,2</sup>	If Y, please input your regulation <sup>1,2</sup>	Agree to proposal from WG? If no, please input your suggestions/thoughts <sup>1,2</sup>
User scope of eIFU <sup>1,2</sup>	For which users may an e-IFU be provided? <sup>1,2</sup> <ul style="list-style-type: none"> <li>All?<sup>1,2</sup></li> <li>Professional Only?<sup>1,2</sup></li> </ul>			
Device Scope of e-IFU <sup>1,2</sup>	For which device types is it permissible to provide an e-IFU. E.g.: <sup>1,2</sup> <ul style="list-style-type: none"> <li>All devices<sup>1,2</sup></li> <li>Software devices (SaMD)<sup>1,2</sup></li> <li>Implants<sup>1,2</sup></li> <li>Specific electronic devices such as:<sup>1,2</sup></li> <li>Fixed installations<sup>1,2</sup></li> <li>Devices with screens<sup>1,2</sup></li> </ul>			
e-IFU formats <sup>1,2</sup>	Which Formats are permitted? (e.g. PDF, HTML, DOC) <sup>1,2</sup>			
Risk mitigation <sup>1,2</sup>	How are risks mitigated including: <sup>1,2</sup> <ul style="list-style-type: none"> <li>physical risks and</li> <li>cyber risks<sup>1,2</sup></li> </ul>			
QMS requirement <sup>1,2</sup>	What are expectations for: <sup>1,2</sup> <ul style="list-style-type: none"> <li>Validation<sup>1,2</sup></li> <li>Version control<sup>1,2</sup></li> <li>Archiving<sup>1,2</sup></li> <li>Continuous lifetime availability<sup>1,2</sup></li> </ul>			
Hard copy supply and equivalence <sup>1,2</sup>	What are requirements for availability of paper version including: <sup>1,2</sup> <ul style="list-style-type: none"> <li>Timeliness<sup>1,2</sup></li> <li>Equivalence<sup>1,2</sup></li> <li>Download/online versions<sup>1,2</sup></li> <li>Avoidance of version mix ups<sup>1,2</sup></li> </ul>			
Content <sup>1,2</sup>	What is the guidance on e-IFU content <sup>1,2</sup>			

Item	e-IFU related Questions	EU	Japan	India	HongKong	Taiwan	Korea
User scope of eIFU	For which users may an e-IFU be provided? •All? •Professional Only?	Professional only And for IVDr, exclusive of near-patient testings Related regulation  (EU) 2021/2226 Article 3(2)	Hospital use only Related regulation: -Medical Devices Act (PMD Act) -Guidance on package insert digitization requirements	All (Not specified)	No specific regulation on eIFU being developed	Not clearly specified, but professional use inclination Related regulation: -Medical Devices Act -Medical Device Product Items Whose Instructions May Be Replaced by Electronic Instructions and Medical Device Firms Shall Indicate the Particulars on the Labels or Package	Yes. Middle Class Devices only used in hospitals. Related regulation: Article 22 of Medical Device Act.
		Manufacturers may provide instructions for use in electronic form instead of in paper form for the devices listed in paragraph 1 under the following conditions: (a) the devices and accessories are intended for exclusive use by professional users; and (b) the use by other persons is not reasonably foreseeable.  IVDR Annex I 20.1(f)  When the device is intended for professional use only, instructions for use may be provided to the user					

<sup>1</sup>Covered Jurisdictions: EU, Japan, India, Hong Kong, China, Taiwan, Australia, Korea, US

# Proposed Work Item (ongoing)

Revisit “Principles of Regulatory Requirements for Electronic Instructions for Use (eIFU)”

## Progress & Plans



# Thank You.

GHWP 26<sup>th</sup> Annual Meeting  
Working Group1 Updates